. 2021 Feb 11;11:3667. doi: 10.1038/s41598-021-83317-7

Table 2.

Prior treatments before pembrolizumab treatment.

Pt	Prior radiation treatments	Number of prior surgeries	Number of prior systemic therapies	Prior systemic therapies^a
1	1. External beam radiation therapy and brachytherapy 2. Chemoradiation^b	0	4	1. Carboplatin/paclitaxel 2. Cisplatin^b 3. Carboplatin/paclitaxel/bevacizumab followed by maintenance bevacizumab^c 4. Topotecan/bevacizumab
2	1. Palliative radiation to the groin and neck	0	6	1. Carboplatin/paclitaxel 2. Cisplatin/topotecan 3. Cetuximab/prexasertib 4. Sapanisertib/afibercept 5. Bimiralisib 6. Selinexor/eribulin^c
3	1. External beam radiation therapy	11	1	1. Carboplatin^c

Prior radiation treatments

Number of prior surgeries

Number of prior systemic therapies

Prior systemic therapies^a

1. External beam radiation therapy and brachytherapy

2. Chemoradiation^b

1. Carboplatin/paclitaxel

2. Cisplatin^b

3. Carboplatin/paclitaxel/bevacizumab followed by maintenance bevacizumab^c

4. Topotecan/bevacizumab

1. Palliative radiation to the groin and neck

1. Carboplatin/paclitaxel

2. Cisplatin/topotecan

3. Cetuximab/prexasertib

4. Sapanisertib/afibercept

5. Bimiralisib

6. Selinexor/eribulin^c

1. External beam radiation therapy

1. Carboplatin^c

Pt: patient.

^aLines of systemic therapy are ordered chronologically.

^bRadiation was given concurrently with weekly cisplatin.

^cLongest duration of disease control on a systemic therapeutic regimen following recurrence.